Welcome to our dedicated page for INTENSITY THERAPEUTICS SEC filings (Ticker: INTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intensity Therapeutics, Inc. (Nasdaq: INTS) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing investors with direct access to official documents and AI-assisted analysis. As a late-stage clinical biotechnology company focused on intratumoral cancer therapies, Intensity’s filings offer detailed insight into its clinical programs, financial position, capital structure, and listing status.
Key filings include periodic reports such as Form 10-K and Form 10-Q, which describe the company’s business, risk factors, and financial statements, as referenced in its proxy materials. Current reports on Form 8-K document material events, including quarterly financial results, clinical trial updates like the INVINCIBLE-4 triple-negative breast cancer study, publication of the IT-01 Phase 1/2 data, amendments to bylaws affecting quorum requirements, Nasdaq compliance communications, and securities purchase agreements for registered direct offerings.
Investors can also review the company’s definitive proxy statements on Schedule 14A, which outline matters submitted to stockholders, such as proposals to approve a reverse stock split within a specified ratio range and potential adjournments of special meetings. These documents provide context on corporate governance decisions and the company’s approach to maintaining Nasdaq Capital Market listing requirements.
On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections, and help explain complex topics such as clinical trial disclosures, capital-raising transactions, and changes to governing documents. Users can quickly locate information on Intensity’s development of INT230-6, its interactions with Nasdaq regarding stockholders’ equity and minimum bid price rules, and other regulatory events. Form 4 and related insider transaction reports, when available, can be reviewed alongside these materials to understand trading activity by directors and officers. This centralized view of INTS filings supports more efficient, document-based research into the company’s oncology-focused business and regulatory history.
BENDER LEWIS H reported acquisition or exercise transactions in this Form 4 filing.
INTENSITY THERAPEUTICS, INC. President and CEO Lewis H. Bender received a grant of 37,749 shares of common stock at $6.11 per share as a fully vested stock award under the company’s 2021 Stock Incentive Plan. The award was made in partial satisfaction of his 2025 bonus, in lieu of cash, at his request. Following this grant, he holds 118,549 common shares directly, with all amounts adjusted for a 1-for-25 reverse stock split effected on February 18, 2026.
Intensity Therapeutics reported a narrower 2025 net loss of $11.6M, improved from $16.3M in 2024, as research and development and general and administrative expenses declined. The company raised over $20M during 2025, ending the year with $11.9M in cash and cash equivalents and a stated cash runway into the second quarter of 2027.
Clinically, preliminary data from the INVINCIBLE-4 breast cancer study showed a pathological complete response rate of 71.4% (5/7) for patients receiving INT230-6 plus standard of care versus 33% (2/6) for standard of care alone, with fewer severe adverse events. A Lancet eBioMedicine publication from the IT-01 study reported a 75% disease control rate and median overall survival of 11.9 months in heavily pretreated metastatic patients. The INVINCIBLE-3 phase 3 sarcoma trial remains paused for new enrollment due to prior funding constraints, though the company continues treating enrolled patients and plans to restart once additional funding is obtained.
Intensity Therapeutics files its annual report describing a late-stage oncology pipeline built around lead intratumoral candidate INT230-6, which combines cisplatin, vinblastine and an amphiphilic enhancer to kill solid tumors locally while stimulating systemic immune responses.
The report highlights completed Phase 1/2 and Phase 2 data showing substantial tumor necrosis, abscopal effects and a generally favorable safety profile, with over 95% of active agents retained in tumors. Ongoing programs include the Phase 3 INVINCIBLE-3 trial in metastatic soft tissue sarcoma and the Phase 2 INVINCIBLE-4 trial in presurgical triple‑negative breast cancer, both designed around dosing based on tumor burden.
Due to funding constraints, new site activations and enrollment in INVINCIBLE-3 and enrollment in INVINCIBLE-4 were temporarily paused, although already-enrolled patients continue treatment and Swiss regulators have approved a revised dosing regimen for INVINCIBLE-4. As of March 26, 2026, the company had 2,540,518 common shares outstanding after a 1-for-25 reverse stock split.
Intensity Therapeutics, Inc. expanded the capacity of its existing at-the-market stock offering program to $60.0 million through a new prospectus supplement. This program lets the company sell common shares from time to time through H.C. Wainwright & Co. LLC.
The company is under no obligation to issue any shares and will decide whether to use the facility based on market conditions and strategic priorities. Management describes the expanded ATM as a way to enhance financial flexibility, giving the company an efficient mechanism to access equity capital if and when it chooses.
Intensity Therapeutics supplements its July 11, 2024 sales agreement to increase the ATM offering size to up to $60,000,000, effective March 23, 2026. The company has previously sold 1,297,655 shares under the agreement for an aggregate gross sales price of $12,029,360.
The ATM Offering remains an at-the-market program through H.C. Wainwright & Co., LLC under the previously disclosed Offering Agreement; all other terms remain unchanged.
Intensity Therapeutics, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing requirement. Nasdaq confirmed that the company’s common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from February 19, 2026 through March 4, 2026, and the matter is now closed.
The company had previously received Nasdaq deficiency notices in June and December 2025 after its share price stayed below $1.00, and was given until June 1, 2026 to regain compliance. Intensity also issued a press release describing its late-stage clinical focus and lead intratumoral cancer therapy candidate INT230-6, which is being evaluated in multiple Phase 2 and Phase 3 studies.
Intensity Therapeutics, Inc. furnished an update to its investor materials, providing an unaudited Financial Highlights Slide through December 31, 2025. The slide, dated March 4, 2026, is available on the company’s investor relations website and is also attached as an exhibit.
The figures in this slide are preliminary and subject to completion of financial closing procedures and management review, so they may differ materially from the final results reported in the company’s year-end financial statements.
Intensity Therapeutics, Inc. approved and implemented a 1-for-25 reverse stock split of its common stock to take legal effect at 4:01 p.m. Eastern Time on February 18, 2026. The shares are expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market on February 19, 2026 under the existing ticker INTS but with a new CUSIP 45828J 202.
Every 25 issued and outstanding shares will be converted into 1 share, with no change to the total number of authorized shares. Fractional shares will not be issued; instead, affected stockholders will receive cash based on the February 18, 2026 closing price. The company estimates that outstanding shares will decrease from approximately 63,346,579 as of February 12, 2026 to approximately 2,533,863, with proportional adjustments to stock options, warrants, convertible securities and equity plan share counts.
Intensity Therapeutics (INTS) furnished an Item 2.02 8‑K announcing its financial results for the three and nine months ended September 30, 2025. The company released the details via a press release attached as Exhibit 99.1. The information is being furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings except as expressly set forth by specific reference.
The 8‑K reiterates standard forward‑looking statement cautions and points readers to the company’s Form 10‑K and recent Form 10‑Qs for risk factors and additional context.
Intensity Therapeutics (NASDAQ: INTS) filed its Q3 2025 10‑Q, showing lower operating spend and continued reliance on equity financing while advancing its clinical programs. Cash and cash equivalents were $7.1 million as of September 30, 2025, up from $2.6 million at year‑end, driven by an at‑the‑market program and public offerings. Q3 net loss was $2.7 million with operating expenses of $2.7 million as R&D and G&A declined year over year. For the nine months, net loss totaled $8.6 million and operating cash use was $6.8 million.
The company paused enrollment in its Phase 3 INVINCIBLE‑3 sarcoma study in March 2025 due to funding constraints and paused new enrollment in the Phase 2 INVINCIBLE‑4 TNBC study in September 2025 to revise dosing. Subsequent to quarter‑end, INTS raised $2.0 million net via ATM and $4.0 million gross in a registered direct offering. Management states available capital is expected to fund current operations until the end of the first quarter of 2027, yet the filing notes substantial doubt about continuing as a going concern given the need for additional financing. Shares outstanding were 49,068,621 as of September 30, 2025; 60,064,965 as of November 5, 2025.